title: Role of bradykinin B2 receptors in the formation of vasogenic brain edema in rats.
abstract: Bradykinin is a mediator of brain edema acting through B2 receptors. However, it is not known if bradykinin mediates the formation of cytotoxic or vasogenic brain swelling. To investigate this question we subjected rats to a cryogenic brain lesion over the left parietal cortex, a model well known to produce predominantly vasogenic brain edema. We inhibited bradykinin B2 receptors with the recently characterized nonpeptide B2 receptor antagonist, LF 16-0687. The animals were assigned to three groups (n = 10, each) receiving 10, or 100 microg/kg/min LF 16-0687 or vehicle (0.9% NaCl). Treatment started 15 min before trauma and was continued for 24 h. Another three groups of animals (n = 10, each) received 10 microg/kg/min LF 16-0687 starting 30 or 60 min after trauma or vehicle (0.9% NaCl) for 24 h. Animals were then sacrificed and swelling and water content of the brain were determined. In the vehicle treated group the traumatized hemisphere swelled by 9.3 +/- 1.1% as compared to the untraumatized contralateral side. Pretreatment with 10 microg/kg/min LF 16-0687 decreased brain swelling significantly to 6.4 +/- 1.3% (p < 0.05). Pre-treatment with 100 microg/kg/min was found to be less effective and did not result in a significant reduction of brain swelling (7.4 + 1.3%). Treatment with LF 16-0687 for 24 h (10 microg/kg/min) started 30 or 60 min after trauma did not reduce brain water content or hemispheric swelling. These results demonstrate that brain injury-mediated bradykinin production induces vasogenic brain edema by B2 receptor stimulation. Our findings further clarify the role of bradykinin in the pathophysiology of brain edema formation and confirm the therapeutic potency of bradykinin B2 receptor inhibition.
authors.affiliation: Institute for Surgical Research, Klinikum Grosshadern, Ludwig-Maximilians University, Munich, Germany. plesnila@icf.med.uni-muenchen.de
authors.forename: N
authors.initials: N
authors.lastname: Plesnila
authors.forename: J
authors.initials: J
authors.lastname: Schulz
authors.forename: M
authors.initials: M
authors.lastname: Stoffel
authors.forename: J
authors.initials: J
authors.lastname: Eriskat
authors.forename: D
authors.initials: D
authors.lastname: Pruneau
authors.forename: A
authors.initials: A
authors.lastname: Baethmann
mesh_terms: D000465:Algorithms; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D001834:Body Water / Q000502:physiology; D065168:Bradykinin Receptor Antagonists; D001929:Brain Edema / Q000188:drug therapy / Q000473:pathology*; D002560:Cerebrovascular Circulation / Q000502:physiology*; D007839:Functional Laterality / Q000502:physiology; D008297:Male; D009929:Organ Size / Q000502:physiology; D011804:Quinolines / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley; D043782:Receptor, Bradykinin B2; D018002:Receptors, Bradykinin / Q000502:physiology*
chemical_list: D065168:Bradykinin Receptor Antagonists; C403051:LF 16-0687; D011804:Quinolines; D043782:Receptor, Bradykinin B2; D018002:Receptors, Bradykinin